Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Dec;8(12):1879-91.
doi: 10.1586/14737175.8.12.1879.

Memory loss in Alzheimer's disease: implications for development of therapeutics

Carl A Gold  1 , Andrew E Budson
Affiliations
Review

Memory loss in Alzheimer's disease: implications for development of therapeutics

Carl A Gold et al. Expert Rev Neurother. 2008 Dec.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease marked by a constellation of cognitive disturbances, the earliest and most prominent being impaired episodic memory. Episodic memory refers to the memory system that allows an individual to consciously retrieve a previously experienced item or episode of life. Many recent studies have focused on characterizing how AD pathology impacts particular aspects of episodic memory and underlying mental and neural processes. This review summarizes the findings of those studies and discusses the effects of current and promising treatments for AD on episodic memory. The goal of this review is to raise awareness of the strides that cognitive neuroscientists have made in understanding intact and dysfunctional memory. Knowledge of the specific memorial processes that are impaired in AD may be of great value to basic scientists developing novel therapies and to clinical researchers assessing the efficacy of those therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Major memory systems in everyday life.
Figure 1
Figure 1
Major memory systems in everyday life.
Figure 2
Figure 2
Selected brain regions involved in episodic memory.
See this image and copyright information in PMC

References

    1. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 2003;348(14):1356–1364. - PubMed
    1. Alzheimer's Association Alzheimer's disease facts and figures 2007. 2007
    1. Ferri C, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112–2117. - PMC - PubMed
    1. Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am. J. Geriatr. Pharmacother. 2005;3(1):39–49. - PubMed
    1. Allegri RF, Butman J, Arizaga RL, et al. Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int. Psychogeriatr. 2007;19(4):705–718. - PubMed

Websites

    1. Montreal Cognitive Assessment www.mocatest.org.
    1. Neurochem announces results from tramiprosate (ALZHEMED™) North American Phase III clinical trial. www.neurochem.com/PR214.htm.

Publication types

MeSH terms